RT Journal Article
SR Electronic
T1 Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.30.24308215
DO 10.1101/2024.05.30.24308215
A1 Ngo, Linh T.
A1 Rekowski, Michaella J.
A1 Koestler, Devin C.
A1 Yorozuya, Takafumi
A1 Saito, Atsushi
A1 Azeem, Imaan
A1 Harrison, Alexis
A1 Demoruelle, M. Kristen
A1 Boomer, Jonathan
A1 England, Bryant R.
A1 Wolters, Paul
A1 Molyneaux, Philip L.
A1 Castro, Mario
A1 Lee, Joyce S.
A1 Solomon, Joshua J.
A1 Koronuma, Koji
A1 Washburn, Michael P.
A1 Matson, Scott M.
YR 2024
UL http://medrxiv.org/content/early/2024/05/31/2024.05.30.24308215.abstract
AB Background Idiopathic interstitial pneumonias (IIPs) such as idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia with autoimmune features (IPAF), present diagnostic and therapeutic challenges due to their heterogeneous nature. This study aimed to identify intrinsic molecular signatures within the lung microenvironment of these IIPs through proteomic analysis of bronchoalveolar lavage fluid (BALF).Methods Patients with IIP (n=23) underwent comprehensive clinical evaluation including pre-treatment bronchoscopy and were compared to controls without lung disease (n=5). Proteomic profiling of BALF was conducted using label-free quantitative methods. Unsupervised cluster analyses identified protein expression profiles which were then analyzed to predict survival outcomes and investigate associated pathways.Results Proteomic profiling successfully differentiated IIP from controls. k-means clustering, based on protein expression revealed three distinct IIP clusters, which were not associated with age, smoking history, or baseline pulmonary function. These clusters had unique survival trajectories and provided more accurate survival predictions than the Gender Age Physiology (GAP) index (C-index 0.794 vs. 0.709). The cluster with the worst prognosis featured decreased inflammatory signaling and complement activation, with pathway analysis highlighting altered immune response pathways related to immunoglobulin production and B cell-mediated immunity.Conclusions The unsupervised clustering of BALF proteomics provided a novel stratification of IIP patients, with potential implications for prognostic and therapeutic targeting. The identified molecular phenotypes underscore the diversity within the IIP classification and the potential importance of personalized treatments for these conditions. Future validation in larger, multi-ethnic cohorts is essential to confirm these findings and to explore their utility in clinical decision-making for patients with IIP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSMM, LTN, DCK and this work were supported by P20GM130423. The proteomics data were collected in the Mass Spectrometry and Proteomics Core facility utilizing the Orbitrap Ascend Tribrid System that was purchased with funds provided by the University of Kansas Cancer Center, which is supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Sapporo Medical University Hospital approved this study (No. 342 201, approved on 02/09/2023).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data available upon reasonable request to authors